Brampton, Canada
Brampton, Canada
SEARCH FILTERS
Time filter
Source Type

HYATTSVILLE, Md. June 1, 2017—The Friedreich’s Ataxia Research Alliance (FARA), National Ataxia Foundation (NAF), Muscular Dystrophy Association (MDA) and Cure FA Foundation will host the first ever Friedreich’s Ataxia (FA) Patient-Focused Drug Development (PFDD) meeting on Friday, June 2, to give patients, families and caregivers the opportunity to speak directly to the U.S. Food and Drug Administration (FDA) about the impact FA has on their daily lives, and their highly unmet need for effective treatments. Friedreich’s ataxia is a debilitating, life-shortening and degenerative neuromuscular disorder. Loss of balance and coordination is the most common presenting symptom typically beginning between the ages of 5 and 15 years, with progression of symptoms leading to loss of ambulation and independence of all activities of daily living. It affects 1 in 50,000 people in the U.S. and is a multi-system disease. Symptoms can also include, muscle loss, scoliosis, vision and hearing impairments, slurred speech, diabetes mellitus and serious heart conditions. Adult or late-onset FA accounts for less than one quarter of all cases. At the upcoming FA PFDD meeting, panelists and audience members will be invited to share their unique insight into what it is like to live with FA, including details about the symptoms that are most troublesome, current strategies for managing those symptoms and their urgent desire for meaningful therapies. The information captured at the meeting will be published in a document called The Voice of the Patient Report and submitted to the FDA to help evaluate future FA therapies — including what will be the first therapy for FA. "The four nonprofit groups that have worked together to organize this meeting have developed a collaborative partnership over time that has supported research toward development of treatments for this rare and devastating disease,” said FARA Executive Director Jen Farmer. “As a product of that collaboration, over 200 people, including about 25 FDA employees, 30 representatives from industry and over 140 patients and family members have registered to attend this meeting, and patients are looking forward to the opportunity to talk about what is meaningful to them in terms of a potential treatment. Although no treatments or cures are available for this devastating disease, there are promising therapies now being developed.” The PFDD initiative is part of the FDA’s commitments under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), which aims to understand the burden of disease from the patient perspective and the factors for treatment decisions. Initiated as a series of FDA-led meetings to learn about 20 specific disorders, the FDA allows external stakeholders to hold their own PFDD meetings to engage the FDA through a formal process. The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), nonprofit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich’s ataxia. FARA's Mission is to marshal and focus the resources and relationships needed to cure FA by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases. The National Ataxia Foundation (NAF) is a nonprofit organization dedicated to finding a cure for Ataxia. NAF funds research for the disease, serving all types of Ataxia. NAF provides the most comprehensive information about Ataxia and is guided by the world’s most renowned Ataxia scientists. Visit ataxia.org to learn how you can get involved in finding the cure. MDA is a national nonprofit organization working to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. Learn how you can fund cures, find care or champion the cause at mda.org. CureFA Foundation is a tax exempt 501(c)(3) organization dedicated to scientific research, building scientific infrastructure, and increasing information availability to the community working towards a cure for FA. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f6f3add-a42f-4ef3-9708-a92ed0a8c97b


HYATTSVILLE, Md. June 1, 2017—The Friedreich’s Ataxia Research Alliance (FARA), National Ataxia Foundation (NAF), Muscular Dystrophy Association (MDA) and Cure FA Foundation will host the first ever Friedreich’s Ataxia (FA) Patient-Focused Drug Development (PFDD) meeting on Friday, June 2, to give patients, families and caregivers the opportunity to speak directly to the U.S. Food and Drug Administration (FDA) about the impact FA has on their daily lives, and their highly unmet need for effective treatments. Friedreich’s ataxia is a debilitating, life-shortening and degenerative neuromuscular disorder. Loss of balance and coordination is the most common presenting symptom typically beginning between the ages of 5 and 15 years, with progression of symptoms leading to loss of ambulation and independence of all activities of daily living. It affects 1 in 50,000 people in the U.S. and is a multi-system disease. Symptoms can also include, muscle loss, scoliosis, vision and hearing impairments, slurred speech, diabetes mellitus and serious heart conditions. Adult or late-onset FA accounts for less than one quarter of all cases. At the upcoming FA PFDD meeting, panelists and audience members will be invited to share their unique insight into what it is like to live with FA, including details about the symptoms that are most troublesome, current strategies for managing those symptoms and their urgent desire for meaningful therapies. The information captured at the meeting will be published in a document called The Voice of the Patient Report and submitted to the FDA to help evaluate future FA therapies — including what will be the first therapy for FA. "The four nonprofit groups that have worked together to organize this meeting have developed a collaborative partnership over time that has supported research toward development of treatments for this rare and devastating disease,” said FARA Executive Director Jen Farmer. “As a product of that collaboration, over 200 people, including about 25 FDA employees, 30 representatives from industry and over 140 patients and family members have registered to attend this meeting, and patients are looking forward to the opportunity to talk about what is meaningful to them in terms of a potential treatment. Although no treatments or cures are available for this devastating disease, there are promising therapies now being developed.” The PFDD initiative is part of the FDA’s commitments under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), which aims to understand the burden of disease from the patient perspective and the factors for treatment decisions. Initiated as a series of FDA-led meetings to learn about 20 specific disorders, the FDA allows external stakeholders to hold their own PFDD meetings to engage the FDA through a formal process. The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), nonprofit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich’s ataxia. FARA's Mission is to marshal and focus the resources and relationships needed to cure FA by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases. The National Ataxia Foundation (NAF) is a nonprofit organization dedicated to finding a cure for Ataxia. NAF funds research for the disease, serving all types of Ataxia. NAF provides the most comprehensive information about Ataxia and is guided by the world’s most renowned Ataxia scientists. Visit ataxia.org to learn how you can get involved in finding the cure. MDA is a national nonprofit organization working to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. Learn how you can fund cures, find care or champion the cause at mda.org. CureFA Foundation is a tax exempt 501(c)(3) organization dedicated to scientific research, building scientific infrastructure, and increasing information availability to the community working towards a cure for FA. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f6f3add-a42f-4ef3-9708-a92ed0a8c97b


HYATTSVILLE, Md. June 1, 2017—The Friedreich’s Ataxia Research Alliance (FARA), National Ataxia Foundation (NAF), Muscular Dystrophy Association (MDA) and Cure FA Foundation will host the first ever Friedreich’s Ataxia (FA) Patient-Focused Drug Development (PFDD) meeting on Friday, June 2, to give patients, families and caregivers the opportunity to speak directly to the U.S. Food and Drug Administration (FDA) about the impact FA has on their daily lives, and their highly unmet need for effective treatments. Friedreich’s ataxia is a debilitating, life-shortening and degenerative neuromuscular disorder. Loss of balance and coordination is the most common presenting symptom typically beginning between the ages of 5 and 15 years, with progression of symptoms leading to loss of ambulation and independence of all activities of daily living. It affects 1 in 50,000 people in the U.S. and is a multi-system disease. Symptoms can also include, muscle loss, scoliosis, vision and hearing impairments, slurred speech, diabetes mellitus and serious heart conditions. Adult or late-onset FA accounts for less than one quarter of all cases. At the upcoming FA PFDD meeting, panelists and audience members will be invited to share their unique insight into what it is like to live with FA, including details about the symptoms that are most troublesome, current strategies for managing those symptoms and their urgent desire for meaningful therapies. The information captured at the meeting will be published in a document called The Voice of the Patient Report and submitted to the FDA to help evaluate future FA therapies — including what will be the first therapy for FA. "The four nonprofit groups that have worked together to organize this meeting have developed a collaborative partnership over time that has supported research toward development of treatments for this rare and devastating disease,” said FARA Executive Director Jen Farmer. “As a product of that collaboration, over 200 people, including about 25 FDA employees, 30 representatives from industry and over 140 patients and family members have registered to attend this meeting, and patients are looking forward to the opportunity to talk about what is meaningful to them in terms of a potential treatment. Although no treatments or cures are available for this devastating disease, there are promising therapies now being developed.” The PFDD initiative is part of the FDA’s commitments under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), which aims to understand the burden of disease from the patient perspective and the factors for treatment decisions. Initiated as a series of FDA-led meetings to learn about 20 specific disorders, the FDA allows external stakeholders to hold their own PFDD meetings to engage the FDA through a formal process. The Friedreich’s Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), nonprofit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich’s ataxia. FARA's Mission is to marshal and focus the resources and relationships needed to cure FA by raising funds for research, promoting public awareness, and aligning scientists, patients, clinicians, government agencies, pharmaceutical companies and other organizations dedicated to curing FA and related diseases. The National Ataxia Foundation (NAF) is a nonprofit organization dedicated to finding a cure for Ataxia. NAF funds research for the disease, serving all types of Ataxia. NAF provides the most comprehensive information about Ataxia and is guided by the world’s most renowned Ataxia scientists. Visit ataxia.org to learn how you can get involved in finding the cure. MDA is a national nonprofit organization working to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. Learn how you can fund cures, find care or champion the cause at mda.org. CureFA Foundation is a tax exempt 501(c)(3) organization dedicated to scientific research, building scientific infrastructure, and increasing information availability to the community working towards a cure for FA. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f6f3add-a42f-4ef3-9708-a92ed0a8c97b


-- MDA announced today that Eddie Wilder, president and CEO of ERA Wilder Realty, has been chosen as MDA's Champion of Spirit award recipient for 2017. "Eddie Wilder has been a great supporter of MDA for many years, and we are proud to honor him with this award" said committee chair, Jeff Lindeman of Sincerely Yours, Inc. The Champion of Spirit award honors local community leaders for their involvement with MDA and supporting our mission to assist families living with neuromuscular diseases such as ALS, and to fund research for lifesaving treatments and cure. The award will be presented at MDA's Toast to Life event on October 5at Embassy Suites.Toast to Life is a fundraising event featuring silent and live auction, including an auction of original art by local children who attend MDA's Summer Camp program. Dave Aiken, longtime MDA supporter and Labor Day Telethon host will emcee the event.Contributions help MDA's efforts in funding groundbreaking research and programs, including support groups and more than 150 MDA Care Centers across the country. MDA is Care Centers at MUSC in Charleston and Georgia Regents University Hospital in Augusta. Funds raised also help send local kids to "the best week of the year" at MDA Summer Camp at no cost to their families at Camp Twin Lake.For tickets to Toast to Life or for more information about MDA's services, please contact the Greater South Carolina MDA office at 803.799.7435 or visit Facebook.com/MDASouthCarolinaMDA is leading the fight to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. We use our collective strength to help kids and adults live longer and grow stronger by finding research breakthroughs across diseases; caring for individuals from day one; and empowering families with services and support in hometowns across America.Learn how you can fund cures, find care and champion the cause at mda.org


WESTMINSTER, Colo.--(BUSINESS WIRE)--DigitalGlobe, Inc. (NYSE: DGI), the global leader in Earth imagery and information about our changing planet, today announced an agreement with MacDonald, Dettwiler and Associates (TSX:MDA) to make RADARSAT-2 data available on DigitalGlobe’s Geospatial Big Data platform, GBDX, unlocking new applications made possible by the combination of optical and radar satellite data. MDA’s RADARSAT-2 satellite collects synthetic aperture radar (SAR) data that gives users the ability to see the Earth both day and night, in all weather conditions. With SAR content on GBDX, users will have ready access to powerful content and tools in the cloud that cost-effectively unlock object and change detection use cases. The first tool that has been integrated into GBDX is based on MDA’s radar-based change detection capability, which provides a reliable means to detect changes caused by human or natural activities. RADARSAT-2’s broad-area imaging capabilities and ability to see through rain and clouds make it a clear choice for monitoring change over large areas at 5 meter resolution levels or better. Change detection can be applied to a time-lapse image stack, allowing users to determine when the change occurred. For example, RADARSAT-2 data could be combined with DigitalGlobe optical imagery to monitor illegal logging on a country-wide scale. Users could tap into GBDX to identify all RADARSAT-2 images for the areas of interest over a given period of time, run automated change detection to identify candidate areas for illicit activity, and then retrieve high-resolution optical imagery of those areas for closer inspection. As applied to defense and intelligence needs, new military structures and activities could be identified. In this case, GBDX would compare historical RADARSAT-2 imagery with new imagery and automatically detect new man-made structures, which appear as bright spots. Further assessment of the structures and activities could then be done using high-resolution optical imagery. “Adding SAR data to the GBDX platform augments our existing 100-petabyte optical imagery library, opening up new use cases our customers have long desired, including the ability to image regardless of clouds or weather on a regular basis,” said Dr. Shay Har-Noy, Vice President and General Manager of DigitalGlobe’s Platform business unit. “Importantly, the GBDX platform enables large-scale computation for users who have only ever used optical imagery, making global-scale, multi-source analytic solutions possible like never before.” DigitalGlobe continues to widen its lead in providing easy-to-use geospatial capabilities to meet a growing range of customer needs. Continuing on its commitment to build the world’s most powerful and complete geospatial platform, and to add the SAR data to GBDX, DigitalGlobe built enhanced features for the processing and management of third-party content. It’s now easier than ever for commercial data providers to put their content on GBDX and earn revenue from the platform’s growing customer base. “Putting our SAR data on the GBDX platform opens up new markets and revenue streams for us,” said David Belton, MDA’s Vice President, Geospatial Services. “DigitalGlobe has developed an industry-leading platform for analyzing and exploiting geospatial content at scale, and making our data accessible to the GBDX developer ecosystem will enhance valuable and complex analytics that are required for applications such as supply chain monitoring, disaster response, and persistent monitoring.” Learn more about GBDX at https://platform.digitalglobe.com/gbdx/ DigitalGlobe is a leading provider of commercial high-resolution Earth observation and advanced geospatial solutions that help decision makers better understand our changing planet in order to save lives, resources and time. Sourced from the world's leading constellation, our imagery solutions deliver unmatched coverage and capacity to meet our customers' most demanding mission requirements. Each day customers in defense and intelligence, public safety, civil agencies, map making and analysis, environmental monitoring, oil and gas exploration, infrastructure management, navigation technology, and providers of location-based services depend on DigitalGlobe data, information, technology and expertise to gain actionable insight. MDA is a global communications and information company providing operational solutions to commercial and government organizations worldwide. MDA’s business is focused on markets and customers with strong repeat business potential, primarily in the Communications sector and the Surveillance and Intelligence sector. In addition, the Company conducts a significant amount of advanced technology development. MDA’s established global customer base is served by more than 4,800 employees operating from 15 locations in the United States, Canada, and internationally. The Company’s common shares trade on the Toronto Stock Exchange under the symbol “MDA.” Certain statements contained herein, including statements about our 2016 outlook, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements relate to future events or future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or “looks forward to” or the negative of these terms or other similar words, although not all forward-looking statements contain these words. Forward-looking statements are based upon our current expectations and assumptions of future events and are subject to risks and uncertainties that could cause our actual results or performance to differ materially from those indicated by such forward-looking statements. Some of the risk and uncertainties that could cause actual results to differ include, but are not limited to: the loss or reduction in scope of any of our primary contracts, or decisions by customers not to exercise renewal options; the availability of government funding for our products and services both domestically and internationally; our ability to meet our obligations under the EnhancedView contract; our reliance on a limited number of vendors to provide certain key products or services to us; breach of our system security measures or loss of our secure facility clearance and accreditation; the loss or damage to any of our satellites; delays in the construction and launch of any of our satellites or our ability to achieve and maintain full operational capacity of all our satellites; loss or damage to the content contained in our ImageLibrary; interruption or failure of our ground systems and other infrastructure; decrease in demand for our imagery products and services; increased competition that may reduce our market share or cause us to lower our prices; changes in political or economic conditions, including fluctuations in the value of foreign currencies, interest rates, energy and commodity prices, trade laws and the effects of governmental initiatives to manage economic conditions; our ability to recruit, hire or retain key employees or a highly skilled and diverse workforce; failure to obtain or maintain required regulatory approvals and licenses; and, changes in U.S. or foreign law or regulation that may limit our ability to distribute our imagery products and services. Additional information concerning these and other risk factors can be found in our filings with the Securities and Exchange Commission, including Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016. We undertake no obligation to revise or update any forward-looking statements, except as required by law. Readers are cautioned not to place undue reliance on any of these forward-looking statements.


News Article | May 10, 2017
Site: www.engineeringnews.co.za

The already high risk of nonpayment in the local construction industry is set to escalate further, owing to South Africa’s recent downgrades by international ratings agencies impacting on the industry’s credit costs, MDA Attorneys’ Chris Bennett has warned. He notes that the “first to feel the pain” of more expensive credit will be the employers, as lenders raise interest rates. This places pressure on employers to fund their projects and reduce their returns, with not many projects being built from cash reserves. “This will mean that more expensive credit will be a widespread blow,” says Bennett. Further, he points out that State construction projects are likely to be the first to be affected, ranging from municipal projects and reaching all State-owned enterprises’ projects. “Already, the controversial nuclear build has been placed in doubt on account of the affordability factor. However, other infrastructure projects are also being placed on hold, including those in crucial areas such as water infrastructure,” he highlights. Besides delaying or blocking new builds, the effect on employers already engaged in projects is significant. They must keep funding them, cancel or suspend them, with the associated results of doing so. Meanwhile, Bennett says pressure is already on employers that are not able to pay their contractors either on time or at all. “This places many contractors in difficult positions, as most contractors will be unable to finance a project beyond 30 days. Those contractors then also take out loans to keep funding the works in anticipation of payment.” Smaller to medium-sized enterprises are most at risk, he says. “Nonpayment or very late payment of contractors is already a significant problem, particularly in the public sector. We anticipate seeing more of this as a result of our junk status,” says Bennett, adding that it will be exacerbated by the lack of regulations ensuring prompt payments. This could possibly lead to increased business rescue and insolvency proceedings in the construction sector. “Parties should not be afraid to exercise their rights and pursue the contractual dispute procedures, judgment for payment certificates, make demands under guarantees, or even terminating the contracts and proceeding to recover damages,” Bennett advised.


News Article | May 10, 2017
Site: www.prweb.com

On Friday, May 5, Dutch Bros locations in all seven states rallied with its communities to raise $970,037 for the Muscular Dystrophy Association to support ALS research and family services. "We were blown away last year by our community’s support, and raising even more this year is beyond amazing. Our community never ceases to amaze us, and it truly shows by the support they showed on Drink One,” said Travis Boersma, Co-founder, Dutch Bros Coffee. Every year, on the first Friday of each May, Dutch Bros rallies for its annual Drink One for Dane day. A day that began in 2006 after Dutch Bros co-founder, Dane Boersma was diagnosed with Amyotrophic Lateral Sclerosis, or ALS. Drink One for Dane began as a way to raise funds and awareness for a disease that is not well understood. In 2009, Dutch Bros lost Dane to this unnerving disease. Drink One for Dane has lived on to honor a man whose wisdom and spirit is still very much a part of Dutch Bros’ day-to-day operations, as well as to raise funds to support the advancement of ALS research and to support family services. ALS is an unsettling disease that affects the parts of the nervous system responsible for voluntary muscle control, severely hindering the ability to speak, move or even breathe. Those diagnosed with the disease typically lose their battle within three to five years. The Muscular Dystrophy Association, better known as MDA, is the world’s leader in ALS research. Funds raised on Drink One for Dane benefit this organization as they continue to support families affected by ALS and to further research into this disease for which a cause and a cure are currently unknown. “How incredibly special that on Drink One for Dane day, the FDA approved the first drug to treat ALS in over 22 years — a proof point reflective of the unprecedented momentum we’re seeing in ALS research,” said MDA Senior Vice President & Scientific Program Director Grace Pavlath, Ph.D. “On this same special day, the Dutch Bros community came together in honor of Dane and in support of continued progress in the fight against ALS. The incredible results of this year’s Drink One for Dane Day are sure to help MDA make the breakthroughs needed to find treatments and cures for ALS.” “It’s pretty crazy to think that on the same day there was significant progress made in a treatment," said Travis. "And for me, I am just super grateful.” With the community’s support on Friday, Dutch Bros was able to donate $970,037. Making Dutch Bros' total donation to the MDA over $3.5 million. These funds will continue to support family services and research efforts as the fight against ALS continues. "With still no cure in site, the money [Dutch Bros] raises through 'Drink One for Dane' provides the kind of hope which is invaluable for all those who are inflicted with ALS. This hope is what keeps our spirits high, giving us the opportunity to live a more normal life," said Dennis Westling, ALS patient. About Dutch Bros Coffee Dutch Bros Coffee is the country’s largest privately held, drive-thru coffee company, with over 280 locations and over 7,000 employees in seven states. The rich, proprietary coffee blend is handcrafted from start to finish. Every ingredient is measured, every process timed, and every cup perfected. With a mission to serve as a role model in the community and committed to doing the right thing, Dutch Bros donates over $2 million annually to nonprofit organizations and local causes selected by local owner-operators. Dutch Bros Coffee is headquartered in Grants Pass, Ore., where it was founded in 1992 by Dane and Travis Boersma, brothers of Dutch descent. To learn more about Dutch Bros, visit http://www.dutchbros.com, like Dutch Bros Coffee on Facebook or follow @DutchBros on Twitter.


VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 9, 2017) - West Kirkland Mining Inc. (TSX VENTURE:WKM)(OTCQB:WKLDF) ("West Kirkland" or the "Company") announces the execution of an exchange agreement (the "EA") with Newmont Mining Corporation ("Newmont") whereby the Company has exchanged all of its rights, title and interests in, and its obligations associated with the TUG Property, located within the Long Canyon Trend of northern Nevada/Utah, for an approximate 1.1% net smelter returns ("NSR") royalty forming part of Newmont's 2.4% NSR royalty on the Hasbrouck Gold Project, located near Tonopah, Nevada, plus the right to US$1.194 million in payments due upon commercial production at Hasbrouck or Three Hills and extinguishment of land fees. The Hasbrouck Gold Project is held by a dedicated limited liability corporation ("LLC") of which the Company holds a 75% interest and of which Clover Nevada LLC, a Nevada LLC wholly-owned by Waterton Precious Metals Fund II Cayman, L.P., holds a 25% interest. The Company now owns for its own account approximately a 1.1% NSR royalty, or 31.4% of the existing 3.5% NSR royalties on the Hasbrouck Gold Project. The existing NSR royalties are over claims hosting the proven and probable reserves and have not been altered by way of this transaction. A September 2016 Updated Pre-Feasibility Study (the "PFS Update") was prepared for the Hasbrouck Gold Project (see "Technical Report and Updated Preliminary Feasibility Study: Hasbrouck and Three Hills Gold-Silver Project, Esmeralda County, Nevada," dated September 14, 2016 and prepared by Thomas L. Dyer, P.E., Paul Tietz, C.P.G., Ryan T. Baker, Herbert C. Osborne and Carl E. Defilippi). Using the PFS Update financial model, the attributable Hasbrouck cash flow acquired by the Company pursuant to the EA is US$9.5 million over the eleven-year project life. At a 5% discount rate, this attributable cash flow amounts to approximately US$7.8 million. At the holding LLC level (75% owned by West Kirkland), the PFS Update estimated a US$120 million NPV (5%) and a 43% IRR, after-tax, with a 3.1 year pay-back at US$1,275/oz Au and US$18.21/oz Ag metal price assumptions. The 1.1% NSR royalty acquired by the Company would add to the Company's share of this modelled value. West Kirkland's CEO, R. Michael Jones, stated, "We are very pleased to complete this transaction with Newmont. Although we believe the TUG Property to be highly prospective, at current gold prices the known deposit is not economic. By comparison, the acquisition of a 1.1% NSR royalty on the Hasbrouck Gold Project plus US$1.194 million in payments and eliminated land fees is very accretive to West Kirkland at today's gold prices. We also see good exploration potential at Hasbrouck and the transaction is attractive across all of the large land position where recent drilling has been successful." The PFS Update estimated open pit proven and probable reserves for 100% of the Hasbrouck Gold Project (based on 100% of the project) totalling 45.3 million tons at a grade of 0.017 oz/ton gold and 0.233 oz/ton silver, containing 762,000 oz gold and 10.6 million oz silver. These reserves were used in the PFS Update and the royalty value model. West Kirkland completed an initial Resource estimate on the TUG deposit in June 2012. The TUG deposit is located within the Long Canyon Trend, which is part of the old Tecoma Mining District. The TUG deposit is a sediment hosted, Carlin style gold deposit that was extensively drilled by the Company and previous operators. An updated NI 43-101 Resource Estimate and Preliminary Economic Assessment ("PEA") by Roscoe Postle Associates USA Ltd. was announced on August 1, 2013 and filed on SEDAR September 13, 2013. Based on a 100% project interest for TUG, the PEA predicted a 26% after-tax IRR and US$9 million NPV (8%) at US$1,525 gold/ US$28 silver. Initial capital cost was projected to be US$24 million. To date the Company has spent approximately US$4.85 million on the TUG Property. After an impairment in a prior period, at year end December 31, 2016 the Company recorded a US$3.37 million carrying value (CAD$4.53 million) for its rights and interests in the TUG Property. The Hasbrouck Gold Project consists of two all-oxide gold-silver deposits eight kilometers apart. Both deposits will be mined in open pits having low stripping ratios and minimal pre-stripping should the project proceed to production. West Kirkland's independent consultants, MDA, produced an updated Pre-feasibility Study in September 2016 which is available on SEDAR and at www.wkmining.com. All necessary permits to construct and operate the Three Hills Mine are in hand, and work to obtain permits for the Hasbrouck Mine is ongoing, with submission of a Plan of Operation to the Bureau of Land Management (BLM) targeted for Q4, 2017. R. Michael Jones P.Eng, CEO for West Kirkland Mining, is a non-independent Qualified Person as defined by NI 43-101. He has reviewed the information contained in this news release and has verified the data by hiring qualified geologists and engineers and has completed a review of the detailed technical information. Mineral Reserve information in this news release relating to the Hasbrouck Gold Project has been developed and approved by Thomas L. Dyer, P.E., of MDA following CIM standards. Mineral Resource information in this news release relating to the TUG Property has been developed and approved by Stuart Collins, P.E., and Luke Evans, P.Eng, of Roscoe Postle Associates USA Ltd (RPA), following CIM standards. West Kirkland Mining utilizes a well-documented system of inserting blanks and standards into the assay stream and has a strict chain of custody. Assays are completed at independent laboratories which have internal quality assurance and quality control systems and procedures. Assays were performed by ALS Chemex Labs Ltd., by fire assay and ICP methods. West Kirkland owns a 75% interest in the Hasbrouck Gold Project in Tonopah, Nevada. The remaining 25% is owned by Clover Nevada LLC, a Nevada limited LLC and 100% subsidiary of Waterton Precious Metals Fund II Cayman, LP. A Pre-feasibility Study with construction-level drawings and all federal and state permits for the phase-one Three Hills Mine provides a ready-to-construct project. Exploration for potential expansion is underway. On behalf of West Kirkland Mining Inc., For further information, please see the Company's website at www.wkmining.com or contact us by email at info@wkmining.com. This press release contains forward-looking information or forward-looking statements (collectively "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: "believe", "expect", "anticipate", "intend", "estimate", "postulate" and similar expressions, or are those, which, by their nature, refer to future events. Forward-looking information in this news release includes, without limitation, the completion of the Prefeasibility Study, the project approach of the Prefeasibility Study and exploration and all information under the heading "Prefeasibility Study Detail", including the Prefeasibility Study budget. Although West Kirkland believes that such timing and expenses as set out in this press release are reasonable, it can give no assurance that such expectations and estimates will prove to be correct. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors, including, but not limited to, the state of the financial markets for the Company's equity securities, the state of the market for gold or other minerals that may be produced generally, variations in the nature, quality and quantity of any mineral deposits that may be located, the Company's ability to obtain any necessary permits, consents or authorizations required for its activities, to raise the necessary capital or to be fully able to implement its business strategies and other risks associated with the exploration and development of mineral properties. The reader is referred to the Company's public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company's profile on SEDAR at www.sedar.com. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


FARMERS BRANCH, TX--(Marketwired - May 9, 2017) - Light Engine Design Corp ( : TLED), is pleased to announce the addition of renowned lighting designer, Mr. Lee Rose, to the Company's Board of Advisors. Mr. Rose's acceptance of this position promises to marry his exceptional artistic and practical application talents to TLED's advanced technology offerings. For over 45 years, Lee Rose has been a force in lighting design for TV, Film, Music and Theater. His design credits include The Golden Globes, The Chelsea Lately show, The MDA Telethon, Larry King Live and the Hollywood party of Dick Clark's New Year's Rockin Eve. Lee's lighting design talents were tapped for feature films including "Bringing Down the House", "Vanilla Sky" and "Almost Famous" and "Southland Tales". His past work includes series and specials for ABC, CBS, NBC, FOX, HBO, Showtime, Comedy Central, CNN, MTV, VH1 and Cinemax. Lee has also designed the lighting for music specials for various artists including; Garth Brooks, Natalie Cole, Johnny Lang, Roy Orbison, Les Paul, Muddy Waters, Bonnie Raitt, Carly Simon, N-Sync, John Tesh, Bruce Willis and Wynonna. "Having worked with Lee on a number of projects, I am thrilled to have someone with his depth of experience and consummate professionalism on board in an advisory capacity," remarked President Kevin Stone. "Input and guidance from end users of this caliber are essential elements in attaining immediate market acceptance and achieving maximal user-friendliness while understanding emerging trends in desired feature sets." Lee has been twice nominated for Emmy Awards for his work with Yanni, including the "Yanni: Live at the Acropolis" concert at the nearly 1500 year old Herod Atticus theatre. He was again nominated for his lighting design work on "Yanni: Tribute", a show that featured concerts taped at the Taj Mahal, in Agra India, which was the first time in history that the Taj was illuminated, and The Forbidden City in Beijing China. In addition, Lee was awarded Lighting Dimensions "Lighting Designer of the Year" for his work on that project. Lee is a member of the International Cinematographers Guild, USITT and the Illuminating Engineering Society. About the Company: Light Engine Design Corp and its wholly-owned subsidiaries, Dallas Lighting & Photonics and Tall Trees LED Company, is focused on becoming an industry pioneer in the research, development, manufacturing, and sales of state-of-the-art Solid-State Lighting (SSL). The Company is specializing in the design of advanced light engines and fixtures employing innovative, unique light emitting diode (LED) and laser phosphor technologies for use in the entertainment, architectural/entertainment (architainment) and frequency-specific biological lighting industries. Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


In addition, the Company has received authorization from the New York Stock Exchange (the "NYSE") to list the MDA common shares, including those issuable to DigitalGlobe shareowners in connection with the transaction on the NYSE.  The Company expects that the MDA common shares issuable in connection with the transaction will begin trading on the Toronto Stock Exchange and the NYSE under the ticker symbol "MDA" on the closing date of the transaction. Certain statements and other information included in this press release constitute "forward-looking information" or "forward-looking statements" (collectively, "forward-looking statements") under applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Statements including words such as "may", "will", "could", "should", "would", "plan", "potential", "intend", "anticipate", "believe", "estimate" or "expect" and other words, terms and phrases of similar meaning are forward-looking statements. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. Such forward-looking statements include, but are not limited to, statements as to MDA's and DigitalGlobe's managements' expectations and assumptions with respect to the anticipated completion of the transaction and timing thereof. Although management of MDA and DigitalGlobe believe that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because MDA and DigitalGlobe can give no assurance that they will prove to be correct. The risks that could cause actual results to differ from current expectations include, but are not limited to: the receipt, in a timely manner, of regulatory and other third party approvals in respect of the transaction, the timing of when MDA common shares issuable in the transaction will begin trading on the Toronto Stock Exchange and NYSE and the ability of MDA and DigitalGlobe to satisfy all conditions for the completion of the transaction. Any such forward-looking statements are subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this press release. Additional information concerning these and other risk factors can be found in MDA's filings with Canadian securities regulatory authorities, which are available online under MDA's profile at www.sedar.com, MDA's filings with the United States Securities and Exchange Commission (the "SEC"), or on MDA's website at www.mdacorporation.com, and in DigitalGlobe's filings with the SEC, including Item 1A of DigitalGlobe's Annual Report on Form 10-K for the year ended December 31, 2016. The forward-looking statements contained in this press release are expressly qualified in their entirety by the foregoing cautionary statements. All such forward-looking statements are based upon data available as of the date of this release or other specified date and speak only as of such date. MDA and DigitalGlobe disclaim any intention or obligation to update or revise any forward-looking statements in this press release as a result of new information or future events, except as may be required under applicable securities legislation. ADDITIONAL INFORMATION ABOUT THE MERGER AND WHERE TO FIND IT In connection with the proposed merger, MDA filed a registration statement on Form F-4 (the "registration statement") with the SEC (Registration No. 333-217512), which included a preliminary proxy statement of DigitalGlobe that also constituted a preliminary prospectus of MDA. The registration statement was declared effective by the SEC on June 16, 2017. MDA and DigitalGlobe began mailing the definitive proxy statement/prospectus to DigitalGlobe's stockholders on or about June 22, 2017. The definitive proxy statement/prospectus contains important information about the proposed merger and related matters. STOCKHOLDERS OF DIGITALGLOBE ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS), CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DIGITALGLOBE AND THE MERGER. Stockholders will be able to obtain copies of the proxy statement/prospectus and other relevant materials (when they become available) and any other documents filed with the SEC by DigitalGlobe or MDA for no charge at the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by MDA also can be obtained free of charge on MDA's corporate website at www.mdacorporation.com  or by contacting MDA's Investor Relations Department by telephone at (604) 331-2044 or by mail to MDA, Attention: Investor Relations Department, 1570 - 200 Burrard Street, Vancouver, BC V6C 3L6. Copies of the documents filed with the SEC by DigitalGlobe also can be obtained free of charge on DigitalGlobe's corporate website at www.digitalglobe.com or by contacting DigitalGlobe's Investor Relations Department by telephone at (303) 684-4000 or by mail to DigitalGlobe, Attention: Investor Relations Department, 1300 W. 120th Ave., Westminster, CO 80234. In addition, in connection with the proposed merger, a management information circular of MDA, describing details of the transaction and other information, was mailed to MDA's shareholders on or about June 26, 2017. The management information circular contains important information about the proposed merger and related matters. SHAREHOLDERS OF MDA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORY AUTHORITIES, INCLUDING THE MANAGEMENT INFORMATION CIRCULAR, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT MDA AND THE MERGER. Additional information about MDA, including all relevant documents filed with Canadian securities regulatory authorities, can be found under its corporate profile on SEDAR at www.sedar.com or by contacting the contact above. MDA (TSX: MDA), is a global communications and information company providing operational solutions to commercial and government organizations worldwide. MDA's business is focused on markets and customers with strong repeat business potential, primarily in the Communications sector and the Surveillance and Intelligence sector. In addition, the Company conducts a significant amount of advanced technology development. MDA's established global customer base is served by more than 4,800 employees operating from 15 locations in the United States, Canada, and internationally. MacDonald, Dettwiler and Associates Ltd. (MDA) common shares trade on the Toronto Stock Exchange under the symbol "MDA."  Upon consummation of the proposed merger, MDA common shares will trade on the NYSE under the symbol "MDA". SSL MDA Holdings, Inc., based in San Francisco, CA, is a wholly owned subsidiary of MacDonald, Dettwiler and Associates Ltd. and serves as the operating company for all MDA businesses. DigitalGlobe is a leading global provider of high-resolution Earth-imagery products and services sourced from our own advanced satellite constellation and third-party providers. Our imagery solutions support a wide variety of users in defense and intelligence, civil agencies, mapping and analysis, environmental monitoring, oil and gas exploration, infrastructure management, Internet portals, and navigation technology. Each day users depend on us to better understand our changing planet in order to save lives, resources and time.

Loading MDA Inc collaborators
Loading MDA Inc collaborators